CPBIO Holding Company Limited (CAIHF)

Market Cap	277.01M +40.7%
Revenue (ttm)	423.98M +12.4%
Net Income	24.43M +67.9%
EPS	0.10
Shares Out	n/a
PE Ratio	11.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	510
Open	0.2775
Previous Close	0.0100
Day's Range	0.2775 - 0.2800
52-Week Range	0.0100 - 0.2800
Beta	3.99
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 17, 2026

About CPBIO Holding Company

CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names. The Investment seg...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 900
• Stock Exchange: OTCMKTS
• Ticker Symbol: CAIHF

Financial Performance

In 2025, CPBIO Holding Company's revenue was $535.91 million, an increase of 74.14% compared to the previous year's $307.75 million. Earnings were $32.06 million, an increase of 187.03%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error